Investor Relations
We invite all current and prospective shareholders, partners, and other interested
parties to browse our web site to learn more about the exciting developments at
our company. Investor inquires can be directed to
Michael Barr at 519-858-5157.
Why Invest in Critical
Outcome Technologies Inc.?
COTI is positioned to help build the pipeline
and increase revenue for all sizes of
pharmaceutical companies
In recent years large pharmaceutical companies have been experiencing slowing sales
growth due to declining pipeline productivity and increasing patent expirations.
For example, approximately 30 brand-name drugs have lost their patents in 2006,
resulting in a total loss of $20 billion in sales. In 2007 this figure is projected
to be $16 billion. This comes at the worst possible time because Big Pharma is at
a 25-year low in new drug approvals (IMS Health).
COTI is positioned to decrease the cost and
time associated with new drug development.
The 2006 Industry Report of the Pharmaceutical Research and Manufacturers of America
(“PRMA”) reports that it takes 10-15 years and costs US$800 million
for a drug to be successfully introduced for patient use. Traditionally, during
drug discovery and pre-clinical pharmaceutical companies evaluate 5,000 or more
compounds for every single successful FDA approval. The PRMA report also suggests
that only 3 of 10 marketed drugs ever produce revenues that match or exceed R&D
costs. Partners who license a COTI targeted library can potentially reduce 2-4 years
off the current pre-clinical drug development timeline.
